This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
The peptide achieves single-digit nanomolar inhibition of SARS-CoV-2.
Why it matters
This research is significant as it addresses the urgent need for effective antiviral treatments against evolving SARS-CoV-2 variants. The findings may lead to new therapeutic options that are less susceptible to mutations.
How the study worked
The study involved structural analysis of the spike protein and testing the peptide's effectiveness in cell-based and virus-based assays.
What this study cannot tell us
The study primarily focuses on in vitro results, which may not fully translate to clinical effectiveness in humans.
Read the original research
Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein.
Proceedings of the National Academy of Sciences of the United States of America, 119(40), e2210990119
Citation
Yang, Kailu; Wang, Chuchu; Kreutzberger, Alex J B; Ojha, Ravi; Kuivanen, Suvi; Couoh-Cardel, Sergio; Muratcioglu, Serena; Eisen, Timothy J; White, K Ian; Held, Richard G; Subramanian, Subu; Marcus, Kendra; Pfuetzner, Richard A; Esquivies, Luis; Doyle, Catherine A; Kuriyan, John; Vapalahti, Olli; Balistreri, Giuseppe; Kirchhausen, Tom; Brunger, Axel T. (2022). Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein.. Proceedings of the National Academy of Sciences of the United States of America, 119(40), e2210990119. https://doi.org/10.1073/pnas.2210990119